Sitagliptin Phosphate and Valbenazine Tosylate

• Generic Name: sitagliptin
• Dosage Forms: n.a.
• Other Brand Names: Januvia

Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Used in combination with immediate- or extended-release metformin given separately or as a fixed combination (Janumet or Janumet XR, respectively) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Used in fixed combination with ertugliflozin (Steglujan) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both drugs is appropriate.

Used in combination with other oral antidiabetic agents (e.g., metformin, a sulfonylurea, a thiazolidinedione [peroxisome proliferator-activated receptor-γ agonist]) or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control with one or more oral antidiabetic agents and/or insulin.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly with both postprandial and fasting plasma glucose elevations.

Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis; insulin is required in these conditions.

• Generic Name: valbenazine
• Dosage Forms: n.a.
• Other Brand Names: Ingrezza

Treatment of tardive dyskinesia.

Tardive dyskinesia is a hyperkinetic movement disorder associated with prolonged use of antipsychotic agents or other antidopaminergic drugs (e.g., metoclopramide).

Prior to the availability of valbenazine, there was no standard treatment for tardive dyskinesia. Management generally included discontinuance or reducing the dosage of the precipitating drug when possible, switching from a conventional or first-generation antipsychotic to an atypical or second-generation antipsychotic, or switching to clozapine therapy.